Bovine lactoferrin ingestion protects against inflammation via IL-11 induction in the small intestine of mice with hepatitis

British Journal of Nutrition

Volumn 111, Issue 10, 2014, Pages 1801-1810

  Kuhara, Tetsuya ^a   Tanaka, Azusa ^a   Yamauchi, Koji ^a   Iwatsuki, Keiji ^a  

^a MORINAGA MILK INDUSTRY CO LTD   (Japan)

Author keywords

Bone morphogenetic protein 2; Hepatitis; IL 11

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA LACTALBUMIN; ASPARTATE AMINOTRANSFERASE; BETA LACTOGLOBULIN; BONE MORPHOGENETIC PROTEIN 2; BOVINE SERUM ALBUMIN; CARBON TETRACHLORIDE; GALACTOSAMINE; INTERLEUKIN 11; INTERLEUKIN 11 RECEPTOR ALPHA; LACTOFERRIN; LIPOPOLYSACCHARIDE; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVATION; ENZYME REGULATION; HEPATITIS; LIVER PROTECTION; MALE; MOUSE; MOUSE MODEL; NONHUMAN; NULL ALLELE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SMALL INTESTINE; SURVIVAL RATE; TRANSGENIC MOUSE; UPREGULATION; ANALYSIS OF VARIANCE; ANIMAL; BLOOD; BOVINE; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; INBRED MOUSE STRAIN; INTRAVENOUS DRUG ADMINISTRATION; LIVER; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ALANINE TRANSAMINASE; ANALYSIS OF VARIANCE; ANIMALS; BONE MORPHOGENETIC PROTEIN 2; CATTLE; DISEASE MODELS, ANIMAL; HEPATITIS; INTERLEUKIN-11; INTESTINE, SMALL; LACTOFERRIN; LIVER; MICE; MICE, INBRED STRAINS; RNA, MESSENGER; SERUM ALBUMIN, BOVINE; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84898903113     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114513004315     Document Type: Article

References (43)

1. Togawa J, Nagase H, Tanaka K, et al. (2002) Lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance. Am J Physiol Gastrointest Liver Physiol 283, G187-G195.
2. Tsubota A, Yoshikawa T, Nariai K, et al. (2008) Bovine lactoferrin potently inhibits liver mitochondrial 8-OHdG levels and retrieves hepatic OGG1 activities in Long-Evans Cinnamon rats. J Hepatol 48, 486-493.
3. Ushida Y, Sekine K, Kuhara T, et al. (1999) Possible chemopreventive effects of bovine lactoferrin on esophagus and lung carcinogenesis in the rat. Jpn J Cancer Res 90, 262-267.
4. Kuhara T, Iigo M, Itoh T, et al. (2000) Orally administered lactoferrin exerts an antimetastatic effect and enhances production of IL-18 in the intestinal epithelium. Nutr Cancer 38, 192-199.
5. Horiuchi Y, Higuchi T, Tatsumi K, et al. (2009) Lactoferrin is associated with a decrease in oocyte depletion in mice receiving cyclophosphamide. Fertil Steril 91, 2069-2078.
6. Guo HY, Jiang L, Ibrahim SA, et al. (2009) Orally administered lactoferrin preserves bone mass and microarchitecture in ovariectomized rats. J Nutr 139, 958-964.
7. Kozu T, Iinuma G, Ohashi Y, et al. (2009) Effect of orally administered bovine lactoferrin on the growth of adenomatous colorectal polyps in a randomized, placebo-controlled clinical trial. Cancer Prev Res 2, 975-983.
8. Tanaka K, Ikeda M, Nozaki A, et al. (1999) Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: a pilot study. Jpn J Cancer Res 90, 367-371.
9. Manzoni P, Rinaldi M, Cattani S, et al. (2009) Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA 302, 1421-1428.
10. Ye XY, Wang HX, Liu F, et al. (2000) Ribonuclease, cell-free translation-inhibitory and superoxide radical scavenging activities of the iron-binding protein lactoferrin from bovine milk. Int J Biochem Cell Biol 32, 235-241.
11. Inubushi T, Kawazoe A, Miyauchi M, et al. (2012) Molecular mechanisms of the inhibitory effects of bovine lactoferrin on lipopolysaccharide-mediated osteoclastogenesis. J Biol Chem 287, 23527-23536.
12. Nozaki A, Ikeda M, Naganuma A, et al. (2003) Identification of a lactoferrin-derived peptide possessing binding activity to hepatitis C virus E2 envelope protein. J Biol Chem 278, 10162-10173.
13. Sferi RM, Dubany M, Boyaka PN, et al. (2004) The mode of oral bovine lactoferrin administration influences mucosal and systemic immune responses in mice. J Nutr 134, 403-409.
14. Yin H, Cheng L, Holt M, et al. (2010) Lactoferrin protects against acetaminophen-induced liver injury in mice. Hepatology 51, 1007-1016.
15. Lehmann V, Freudenberg MA & Galanos C (1987) Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine- treated mice. J Exp Med 165, 657-663.
16. Nakatsuka R, Taniguchi M, Hirata M, et al. (2007) Transient expression of bone morphogenic protein-2 in acute liver injury by carbon tetrachloride. J Biochem 141, 113-119.
17. Yamaguchi M, Matsuura M, Kobayashi K, et al. (2001) Lactoferrin protects against development of hepatitis caused by sensitization of Kupffer cells by lipopolysaccharide. Clin Diagn Lab Immunol 8, 1234-1239.
18. Kuwata H, Yamauchi K, Teraguchi S, et al. (2001) Functional fragments of ingested lactoferrin are resistant to proteolytic degradation in the gastrointestinal tract of adult rats. J Nutr 131, 2121-2127.
19. Kuhara T, Yamauchi K, Tamura Y, et al. (2006) Oral administration of lactoferrin increases NK cell activity in mice via increased production of IL-18 and type I IFN in the small intestine. J Interf Cytok Res 26, 489-499.
20. Kuhara T, Yamauchi K & Iwatsuki K (2012) Bovine lactoferrin induces interleukin-11 production in a hepatitis mouse model and human intestinal myofibroblasts. Eur J Nutr 51, 343-351.
21. Du X & Williams DA (1997) Interleukin-11: review of molecular, cell biology, and clinical use. Blood 89, 3897-3908.
22. Kawakami T, Takahashi T, Shimizu H, et al. (2006) Highly liver-specific heme oxygenase-1 induction by interleukin-11 prevents carbon tetrachloride-induced hepatotoxicity. Int J Mol Med 18, 537-546.
23. Trepicchio WL, Wang L, Bozza M, et al. (1997) IL-11 regulates macrophage effector function through the inhibition of nuclear factor-kB. J Immunol 159, 5661-5670.
24. Sims NA, Jenkins BJ, Nakamura A, et al. (2005) Interleukin-11 receptor signaling is required for normal bone remodeling. J Bone Miner Res 20, 1093-1102.
25. Bao L, Devi S, Bowen-Shauver J, et al. (2006) The role of interleukin-11 in pregnancy involves up-regulation of a2-macroglobulin gene through Janus kinase 2-signaling transducer and activator of transcription 3 pathway in the deciduas. Mol Endocrinol 20, 3240-3250.
26. Nandurkar HH, Robb L, Tarlinton D, et al. (1997) Adult mice with targeted mutation of the interleukin-11 receptor (IL11Ra) display normal hematopoiesis. Blood 90, 2148-2159.
27. Jonker AM, Dijkhuis FW, Hardonk MJ, et al. (1994) Immunohistochemical study of hepatic fibrosis induced in rats by multiple galactosamine injections. Hepatology 19, 775-781.
28. Iwasa M, Kaito M, Ikoma J, et al. (2002) Lactoferrin inhibits hepatitis C virus viremia in chronic hepatitis C patients with high viral loads and HCV genotype 1b. Am J Gastroenterol 97, 766-767.
29. Ueno H, Sato T, Yamamoto S, et al. (2006) Randomized, double-blind, placebo-controlled trial of bovine lactoferrin in patients with chronic hepatitis C. Cancer Sci 97, 1105-1110.
30. Konishi M, Iwasa M, Yamauchi K, et al. (2006) Lactoferrin inhibits lipid peroxidation in patients with chronic hepatitis C. Hepatol Res 36, 27-32.
31. Qui BS, Pfeiffer CJ & Keith JC Jr (1996) Protection by recombinant human interleukin-11 against experimental TNBinduced colitis in rats. Dig Dis Sci 41, 1625-1630.
32. Bozza M, Bliss JL, Maylor R, et al. (1999) Interleukin-11 reduces T-cell-dependent experimental liver injury in mice. Hepatology 30, 1441-1447.
33. Ellis M, Zwaan F, Hedstrom U, et al. (2003) Recombinant human interleukin 11 and bacterial infection in patients with haematological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomized trial. Lancet 361, 275-280.
34. Trepicchio WL, Ozawa M, Walters IB, et al. (1999) Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 104, 1527-1537.
35. Yamauchi K, Hiruma M, Yamazaki N, et al. (2000) Oral administration of bovine lactoferrin for treatment of tinea pedis. A placebo-controlled, double-blind study. Mycoses 43, 197-202.
36. Lawitz EJ, Hepburn MJ & Casey TJ (2004) A pilot study of interleukin-11 in subjects with chronic hepatitis C and advanced liver disease nonresponsive to antiviral therapy. Am J Gastroenterol 99, 2359-2364.
37. Babitt JL, Huang FW, Xia Y, et al. (2007) Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest 117, 1933-1939.
38. Chen D, Zhao M & Mundy GR (2004) Bone morphogenetic proteins. Growth Factors 22, 233-241.
39. Takeuchi Y, Watanabe S, Ishii G, et al. (2002) Interleukin-11 as a stimulatory factor for bone formation prevents bone loss with advancing age in mice. J Biol Chem 277, 49011-49018.
40. Nakashima K, Yanagisawa M, Arakawa H, et al. (1999) Synergistic signaling in fetal brain by stat3-smad1 complex bridged by p300. Science 284, 479-482.
41. Hardwick JC, Van Den Brink GR, Bleuming SA, et al. (2004) Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon. Gastroenterology 126, 111-121.
42. Hori M, Sawai H, Tsuji Y, et al. (2006) Bone morphogenetic protein-2 counterregulates interleukin-18 mRNA and protein in MC3T3-E1 mouse osteoblastic cells. Connect Tissue Res 47, 124-132.
43. Ain R, Trinh ML & Soares MJ (2004) Interleukin-11 signaling is required for the differentiation of natural killer cells at the maternal-fetal interface. Dev Dyn 231, 700-708.